BOMBESIN ANTAGONISTS

Award Information

Agency: Department of Health and Human Services	Branch: N/A	Award ID: 18994	Program Year/Program: 1992 / SBIR
Agency Tracking Number: 18994	Solicitation Year: N/A	Solicitation Topic Code: N/A	Solicitation Number: N/A

Small Business Information: Peptide Technolgies Corp.
PO BOX 368 MAIN 125 MICHIGAN AVE NE Washington, DC 20017
View profile »

Woman-Owned: Yes

Minority-Owned: No

HUBZone-Owned: No

Phase 1: Fiscal Year: 1992

Title: BOMBESIN ANTAGONISTS

Agency: HHS

Contract: N/A

Award Amount: $50,000.00

Abstract:
RECENT BOMBESIN AND GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONISTS HAVE BEEN DEMONSTRATED TO B E QUITE POTENT IN INHIBITING THE EFFECTS OF BOMBESIN IN PANCREATIC ACINAR CELLS, BRAIN MEMBRANES, SWISS 3T3 FIBROBLASTS, AND HUMAN SMALL CELL LUNG CARCINOMA (SCLC). HOWEVER, THESE ANTAGONISTS DO NOT DISPLAY COMPARABLE HIGH POTENCY IN INHIBITING THE PROLIFERATION OF HUMAN SMALL CELL LUNG CARCINOMA. CERTAIN BOMBESIN ANTAGONISTS DO INHIBIT PROLIFERATION OF CLONAL GROWTH OF SCLC AND HAVE BEEN FOUND TO INHIBIT SCLC TUMOR GROWTH IN VIVO. STUDIES WILL BE CONDUCTED TO DESIGN AND SYNTHESIZE MORE STABLE COMPOUNDS FROM THE INHIBITOR STRUCTURES BY CYCLIZATION AND DESCREASING THEIR SUSCEPTIBILITY TO PROTEOLYTIC DEGRADATION. NOVEL GROUPS WILL BE ADDED TO THE ANTAGONISTS TO INCREASE INTERACTION WITH SCLC RECEPTOR. THE EFFECT ON CLONAL GROWTH OF HUMAN SCLC CELLS WILL BE MEASURED AS AN INDICATOR OF IN VIVO ANTI-TUMOR POTENTIAL.

Principal Investigator:
Martha Knight
8009663384

Business Contact:

Small Business Information at Submission:

Peptide Technologies Corp
125 Michigan Avenue Ne Washington, DC 20017

EIN/Tax ID:

DUNS: N/A

Number of Employees: N/A

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No